Skip to Main Content

Hari Deshpande, MD

Associate Professor of Medicine (Medical Oncology)

Contact Information

Hari Deshpande, MD

Mailing Addresses

  • PO Box 208028

    333 Cedar Street,

    New Haven, CT, 06520-8028

    United States

  • Smilow Cancer Hospital at Yale New Haven

    4th Floor Multidisciplinary Clinic

    New Haven, CT, 06511

    United States

Research Summary

I have been involved in clinical trials since joining Yale in 2004. My main interests are in sarcoma, thyroid cancers and cancers of unknown primary. I am also part of the head and neck and GU cancer teams and participate in their trials. My current research includes new treatments for thyroid cancers as well as types of sarcoma. I will also be also looking at the effect of COVID on the inpatient medical oncology consult service at Yale. I am fortunate to be an investigator in over 20 trials of different therapies in Sarcomas, head and neck cancers, thyroid cancers and GU cancers

Extensive Research Description

The clinical trials I am involved with change frequently - I encourage interested people to view the Yale Cancer Center Clinical Trials website. http://yalecancercenter.org/patient/trials/

Sarcoma; Cancers of unknown primary; Thyroid cancer

Research Interests

Chondrosarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Soft Tissue Neoplasms; Sarcoma, Synovial; Thyroid Neoplasms; Neoplasms, Connective and Soft Tissue; Liposarcoma, Myxoid

Clinical Trials

ConditionsStudy Title
PediatricsPrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Lip, Oral Cavity and Pharynx; Other Skin; Soft TissueA Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
ProstateA Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
ProstateA Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Other Urinary; Urinary BladderA Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor
Urinary BladderA Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma
Other UrinaryA Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma
Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Thyroid; Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
ProstatePhase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Urinary BladderPhase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)
Esophagus; Larynx; Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
ProstatePhase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With Small Cell Neuroendocrine Prostate Cancer
Other SkinA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)
Esophagus; Larynx; Lip, Oral Cavity and PharynxRandomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Prostate; Phase IA Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer Who Have Progressed on at Least Two Prior Systemic Therapies.
LungA Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
Other Urinary; Urinary BladderPhase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Lip, Oral Cavity and PharynxPhase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Bones and Joints; Brain and Nervous System; Leukemia, not otherwise specified; Leukemia, other; Lymphoid LeukemiaNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Other Urinary; Urinary BladderPhase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation